| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/HEPR.12825 |
| P698 | PubMed publication ID | 27689765 |
| P50 | author | Harald Grallert | Q29840626 |
| Tonia de Las Heras Gala | Q42439274 | ||
| Christian von Loeffelholz | Q42440959 | ||
| Michael Bauer | Q50638837 | ||
| Igor M Sauer | Q57009734 | ||
| Paula Singmann | Q57064434 | ||
| P2093 | author name string | Paul Horn | |
| Andreas F H Pfeiffer | |||
| Jennifer Kriebel | |||
| Simone Wahl | |||
| Regine Heller | |||
| Johan F Lock | |||
| Martin Stockmann | |||
| Gerhard Jahreis | |||
| Andreas L Birkenfeld | |||
| Ralf A Claus | |||
| Stefanie Lieske | |||
| Tonia de Las Heras Gala | |||
| Christian von Loeffelholz | |||
| Stephanie Döcke | |||
| Nathaniel Raschzok | |||
| P2860 | cites work | Guidelines for the use and interpretation of assays for monitoring autophagy | Q21996341 |
| Diagnosis and Classification of Diabetes Mellitus | Q22255454 | ||
| Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1alpha pathway | Q24607012 | ||
| Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man | Q26776977 | ||
| Amino acids and mTORC1: from lysosomes to disease | Q27009377 | ||
| Regulation of hepatic lipogenesis by the transcription factor XBP1 | Q28507784 | ||
| Autophagy regulates lipid metabolism | Q29547421 | ||
| Design and validation of a histological scoring system for nonalcoholic fatty liver disease | Q29614930 | ||
| Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy | Q29615616 | ||
| Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease | Q29619334 | ||
| Deficient chaperone-mediated autophagy in liver leads to metabolic dysregulation | Q34143516 | ||
| Fibroblast growth factor 21 is regulated by the IRE1α-XBP1 branch of the unfolded protein response and counteracts endoplasmic reticulum stress-induced hepatic steatosis | Q34396839 | ||
| Coactivation of Foxa2 through Pgc-1beta promotes liver fatty acid oxidation and triglyceride/VLDL secretion | Q34651716 | ||
| Independent Association between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: A Systematic Review and Meta-Analysis | Q34729697 | ||
| Mapping autophagy on to your metabolic radar | Q35696469 | ||
| Fatty acid distribution of cord and maternal blood in human pregnancy: special focus on individual trans fatty acids and conjugated linoleic acids | Q35809110 | ||
| Elevated TCA cycle function in the pathology of diet-induced hepatic insulin resistance and fatty liver | Q35958436 | ||
| The Xbp1s/GalE axis links ER stress to postprandial hepatic metabolism | Q36497151 | ||
| Nonalcoholic steatohepatitis: pathologic features and differential diagnosis | Q36580461 | ||
| Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease | Q36856713 | ||
| Endoplasmic reticulum stress is reduced in tissues of obese subjects after weight loss | Q37105351 | ||
| AMPK: a key regulator of energy balance in the single cell and the whole organism. | Q37249357 | ||
| Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis | Q37299002 | ||
| Glycine and urea kinetics in nonalcoholic steatohepatitis in human: effect of intralipid infusion | Q37337683 | ||
| Insulin resistance and fuel homeostasis: the role of AMP-activated protein kinase | Q37401940 | ||
| Suppression of the mTORC1/STAT3/Notch1 pathway by activated AMPK prevents hepatic insulin resistance induced by excess amino acids | Q37575390 | ||
| From sugar to fat: How the transcription factor XBP1 regulates hepatic lipogenesis | Q37596560 | ||
| Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes | Q37624982 | ||
| Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials | Q37978785 | ||
| Endoplasmic reticulum stress in nonalcoholic fatty liver disease | Q38027194 | ||
| Clinical Review: Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. | Q38072021 | ||
| Mitochondrial dysfunction in non-alcoholic fatty liver disease and insulin resistance: cause or consequence? | Q38126549 | ||
| AICAR, an AMPK activator, has protective effects on alcohol-induced fatty liver in rats | Q38317237 | ||
| FGF21 treatment ameliorates alcoholic fatty liver through activation of AMPK-SIRT1 pathway | Q38943985 | ||
| Lipid-induced endoplasmic reticulum stress in liver cells results in two distinct outcomes: adaptation with enhanced insulin signaling or insulin resistance | Q39388424 | ||
| ER stress and autophagy dysfunction contribute to fatty liver in diabetic mice | Q39716920 | ||
| AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells | Q40515180 | ||
| Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis | Q40960591 | ||
| Pigment epithelium-derived factor (PEDF) suppresses IL-1β-mediated c-Jun N-terminal kinase (JNK) activation to improve hepatocyte insulin signaling | Q41956357 | ||
| Fatty acid metabolism in the liver, measured by positron emission tomography, is increased in obese individuals | Q42946610 | ||
| Comparison of lipid and fatty acid composition of the liver, subcutaneous and intra-abdominal adipose tissue, and serum | Q43637127 | ||
| Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes | Q43833528 | ||
| Elevated hepatic chemerin mRNA expression in human non-alcoholic fatty liver disease | Q44473003 | ||
| Abrogation of hepatic ATP-citrate lyase protects against fatty liver and ameliorates hyperglycemia in leptin receptor-deficient mice | Q46141813 | ||
| Liver X receptor in cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease. | Q46442905 | ||
| ChREBP*Mlx is the principal mediator of glucose-induced gene expression in the liver | Q50336015 | ||
| P433 | issue | 9 | |
| P304 | page(s) | 890-901 | |
| P577 | publication date | 2016-09-30 | |
| P1433 | published in | Hepatology Research | Q15752035 |
| P1476 | title | Increased lipogenesis in spite of upregulated hepatic 5'AMP-activated protein kinase in human non-alcoholic fatty liver | |
| P478 | volume | 47 |
| Q55546958 | Deterioration of Organ Function As a Hallmark in Sepsis: The Cellular Perspective. |
| Q38287666 | Endotoxemia-mediated activation of acetyltransferase P300 impairs insulin signaling in obesity |
| Q41075841 | Growth hormone reverses dyslipidemia in adult offspring after maternal undernutrition |
| Q93164524 | Metabolic Biomarkers in Aging and Anti-Aging Research |
| Q89220189 | Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease |
| Q90597304 | Sustained ER stress promotes hyperglycemia by increasing glucagon action through the deubiquitinating enzyme USP14 |
| Q58802792 | Thiazolidinedione induces a therapeutic effect on hepatosteatosis by regulating stearoyl-CoA desaturase-1, lipase activity, leptin and resistin |
Search more.